Search Results: All recruiting trials found

Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

27 trials found

Apatinib Mesylate
Apatinib Mesylate (Rivoceranib) Versus Standard Second-line TKI in the Treatment of Advanced GIST
       
Imatinib + Sunitinib + Regorafenib
GIST: Assessment of Tumor Mutations and TKI Plasma Exposure
       
Ripretinib
Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy
       
Surgery
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
       
MAAT
Cognitive Impairment in GIST Patients on Tyrosine Kinase Inhibitor Therapy: Cognitive Behavioral Therapy to Improve Cognitive Symptoms (GIST-MAAT)
0
       
HQP1351
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
1
       
IDRX-42
A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]
1
       
INBRX-109 + Temozolomide
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
1
       
NB003
A Study of NB003 in Patients With Advanced Malignancies
1
       
neoBOMB1
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)
1
       
Pimitesib
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
1
       
Avelumab + Axitinib
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)
2
       
Belzutifan
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
2
       
ctDNA plus Sunitinib or Regorafenib
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
2
       
Imatinib
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
2
       
Imatinib
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors (ZJGIST-01)
2
       
Imatinib
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
2
       
Imatinib + Atezolizumab
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)
2
       
Lenvatinib
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)
2
       
LOXO-101
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors
2
       
Paclltaxel
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
2
       
Bezuclastinib plus Sunitinib
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
3
       
Famitinib
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
3
       
Imatinib
Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)
3
       
Ripretinib
A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)
3
       
DCC-3116 + Ripretinib
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
1/2
       
Regorafenib + Avelumab
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)
1/2